Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02999399 · ClinicalTrials.gov registry record · Phase 1
Glucobrassicin-Brussel Sprout Effect on D10 Phe Metabolism
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT02999399 is a Phase 1 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 39 participants.
The verdict
NCT02999399, a Phase 1 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
To determine whether glucobrassicin-rich Brussels sprouts can favorably modify the metabolism of the polycyclic aromatic hydrocarbon deuterated phenanthrene (\[D10\]phe) in current and former smokers
Interventions
- OTHER Brussel Sprouts
- DRUG Deuterated Phenanthrene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-12-01 |
| Est. Completion | 2021-03-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02999399
The ClinicalTrials.gov registry entry for NCT02999399 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brussel Sprouts is the first listed.
NCT02999399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02999399 about?
NCT02999399 is a clinical study titled "Glucobrassicin-Brussel Sprout Effect on D10 Phe Metabolism". To determine whether glucobrassicin-rich Brussels sprouts can favorably modify the metabolism of the polycyclic aromatic hydrocarbon deuterated phenanthrene (\[D10\]phe) in current and former smokers
What is the current status of trial NCT02999399?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2016-12-01. Estimated completion is 2021-03-22.
What interventions are being tested in trial NCT02999399?
The interventions under investigation include: Brussel Sprouts (OTHER), Deuterated Phenanthrene (DRUG).
Who is sponsoring clinical trial NCT02999399?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.